CARLOMAGNO, Chiara
CARLOMAGNO, Chiara
DIPARTIMENTO DI MEDICINA CLINICA E CHIRURGIA
Role of sphingosine kinase 1 (SphK1) on cetuximab resistance in colorectal cancer models
2012 Bianco, Roberto; R., Rosa; L., Nappi; Formisano, Luigi; V., Damiano; C., D'Amato; A. P., de Maio; Marciano, Roberta; Malapelle, Umberto; Troncone, Giancarlo; Carlomagno, Chiara; DE STEFANO, Alfonso; G., Tortora; DE PLACIDO, Sabino
Guillain Barrè syndrome associated with gastric cancer: paraneoplastic syndrome or immunological disorder?
2010 Colantuoni, Maria; Matano, E; Alfieri, Salvatore; DE PLACIDO, Sabino; Carlomagno, Chiara
Cancro del colon-retto
1999 Carlomagno, Chiara; DE PLACIDO, Sabino; Bianco, Ar
FOLFOXIRI plus bevacizumab (bev) versus FOLFIRI plus bev as first-line treatment of metastatic coloectal cancer (MCRC): results of the phase III tandomized TRIBE trial
2013 Luopakis, F; Cremolini, C; Masi, G; Lonardi, S; Zagonel, V; Trenta, P; Tomasello, G; Ronzoni, M; Ciuffreda, L; Zaniboni, A; Tonini, G; Buonadonna, A; Valsuani, C; Chiara, S; Carlomagno, Chiara; Boni, C; Marcucci, L; Boni, L; Falcone, A.
MULTIPLE PRIMARY MALIGNANT NEOPLASM AND FAMILIAR ANAMNESIS
2009 M., Colantuoni; Carlomagno, Chiara; L., Cannella; S., Alfieri; DE STEFANO, Alfonso; Ca, Cella; DE PLACIDO, Sabino
Phase I-II study of xelox and bevacizumab plus erlotinib in sequential combination (XELOX-TARAV) in first line colorectal cancer: run in part
2007 G., Tortora; Carlomagno, Chiara; Bianco, Roberto; Daniele, G; Pepe, S; Leopardo, D; Marciano, Roberta; DE LAURENTIIS, Michelino; F., Ciardiello; DE PLACIDO, Sabino
Double complete response in MCRC patient
2009 DE STEFANO, Alfonso; Carlomagno, Chiara; L., Cannella; S., Alfieri; M., Colantuoni; Ca, Cella; DE PLACIDO, Sabino
Raltitrexed versus standard leucovorin-modulated 5Fluorouracil: results form the randomized phase III Pan-European Trial in Adjuvant Colon Cancer 01 (PETACC-1).
2008 Popov, I; Carrato, A; Sobrero, A; Vincent, M; Kerr, D; Labianca, R; Bianco, Ar; El Serafi, M; Bedenne, L; Paillot, B; Mini, E; Sanches, E; Welch, J; Colette, L; Praet, M; Wils, J; Carlomagno, Chiara
Combination chemotherapy with CMF (Cyclophosphamide, Metotrexate, 5-Fluorouracil versus CNF (Mitoxantrone, Fluorouracil, Cyclophosphamide) in advanced breast cancer. A multicenter randomized study.
1993 Lorusso, V.; De Lena, M.; Lopez, M.; DE PLACIDO, Sabino; Vici, P.; Piano, A.; Palomba, G.; Carlomagno, Chiara; D’Aprile, M.; Fosser, V.; Brandi, M.; Bianco, A. R.
Effect of p53 Activity on the Sensitivity of Human Glioblastoma Cells to PARP-1 Inhibitor in Combination with Topoisomerase I Inhibitor or Radiation
2014 Francesco, Sabbatino; Celeste, Fusciello; Domenico, Somma; Pacelli, Roberto; Ravin, Poudel; David, Pepin; Leonardi, Antonio; Carlomagno, Chiara; Giuseppina Della Vittoria, Scarpati; Soldano, Ferrone; Stefano, Pepe
Ipilimumab in the treatment of metastatic melanoma: management of adverse events
2014 Giuseppina Della Vittoria, Scarpati; Celeste, Fusciello; Francesco, Perri; Francesco, Sabbatino; Soldano, Ferrone; Carlomagno, Chiara; Stefano, Pepe
Predictive factors of complete response to neoadjuvant chemoradiotherapy in patients with rectal cancer
2010 Carlomagno, Chiara; Stefano, Pepe; D'Armiento, FRANCESCO PAOLO; D'Armiento, Maria; Lucia, Cannella; DE STEFANO, Alfonso; Anna, Crispo; Marcella, Giordano; DE PLACIDO, Sabino
Bevacizumab maintenance in metastatic colorectal cancer: How long?
2014 DE STEFANO, Alfonso; Moretto, R; Cella, Ca; Romano, Fj; Raimondo, L; Fiore, G; Di Pietro, F; Pepe, S; DE PLACIDO, Sabino; Carlomagno, Chiara
Cancro del colon-retto
2003 Carlomagno, Chiara; DE PLACIDO, Sabino; Bianco, Ar
Bevacizumab related arterial hypertension as a predictive marker in metastatic Colorectal Cancer (mCRC) patients
2011 DE STEFANO, Alfonso; Carlomagno, Chiara; Stefano, Pepe; Bianco, Roberto; DE PLACIDO, Sabino
Trastuzumab-associated cardiac adverse effects in the Herceptin adjuvant trial.
2007 Suter, Tm; Procter, M; van Veldhuisen, Dj; Muscholl, M; Bergh, J; Carlomagno, Chiara; Perren, T; Passalacqua, R; Bighin, C; Klijn, Jgm; Ageev, Ft; Hitre, E; Groetz, J; Iwata, H; Knap, M; Gnant, M; Muehlbauer, S; Spence, A; Gelber, Rd; Piccart, M.
Measurement of neovascularization is an independent prognosticator of survival in node-negative breast cancer patients with long-lerm follow-up.
1999 DE PLACIDO, Sabino; Carlomagno, Chiara; Ciardiello, F; DE LAURENTIIS, Michelino; Pepe, Stefano; Ruggiero, A; Tortora, Giampaolo; Panico, L; D’ ANTONIO, A; Pettinato, Guido; Petrella, Giuseppe; Bianco, Ar
Bevacizumab as 4th line treatment in metastatic colorectal cancer
2009 L., Cannella; Carlomagno, Chiara; DE STEFANO, Alfonso; S., Alfieri; M., Colantuoni; Ca, Cella; DE PLACIDO, Sabino
EGFR mutations detected on cytology samples by a centralized laboratory reliably predict response to gefitinib in non-small cell lung carcinoma patients.
2013 Malapelle, Umberto; Bellevicine, Claudio; DE LUCA, Caterina; Salatiello, M; DE STEFANO, Alfonso; Rocco, D; de Rosa, N; Vitiello, F; Russo, S; Pepe, F; Iaccarino, A; Micheli, P; Illiano, A; Carlomagno, Chiara; Piantedosi, Fv; Troncone, Giancarlo
Poly(adenosine diphosphate-ribose) polymerase 1 expression in malignant melanomas from photoexposed areas of the head and neck region.
2005 Staibano, Stefania; Pepe, S; Lo Muzio, L; Somma, P; Mascolo, Massimo; Argenziano, G; Scalvenzi, Massimiliano; Salvatore, G; Fabbrocini, Gabriella; Molea, Guido; Bianco, Ar; Carlomagno, Chiara; DE ROSA, Gaetano
Titolo | Tipologia | Data di pubblicazione | Autore(i) | File |
---|---|---|---|---|
Role of sphingosine kinase 1 (SphK1) on cetuximab resistance in colorectal cancer models | 1.5 Abstract in rivista | 2012 | Bianco, Roberto; R., Rosa; L., Nappi; Formisano, Luigi; V., Damiano; C., D'Amato; A. P., de Maio; Marciano, Roberta; Malapelle, Umberto; Troncone, Giancarlo; Carlomagno, Chiara; DE STEFANO, Alfonso; G., Tortora; DE PLACIDO, Sabino | |
Guillain Barrè syndrome associated with gastric cancer: paraneoplastic syndrome or immunological disorder? | 1.1 Articolo in rivista | 2010 | Colantuoni, Maria; Matano, E; Alfieri, Salvatore; DE PLACIDO, Sabino; Carlomagno, Chiara | |
Cancro del colon-retto | 2.1 Contributo in volume (Capitolo o Saggio) | 1999 | Carlomagno, Chiara; DE PLACIDO, Sabino; Bianco, Ar | |
FOLFOXIRI plus bevacizumab (bev) versus FOLFIRI plus bev as first-line treatment of metastatic coloectal cancer (MCRC): results of the phase III tandomized TRIBE trial | 1.5 Abstract in rivista | 2013 | Luopakis, F; Cremolini, C; Masi, G; Lonardi, S; Zagonel, V; Trenta, P; Tomasello, G; Ronzoni, M; Ciuffreda, L; Zaniboni, A; Tonini, G; Buonadonna, A; Valsuani, C; Chiara, S; Carlomagno, Chiara; Boni, C; Marcucci, L; Boni, L; Falcone, A. | |
MULTIPLE PRIMARY MALIGNANT NEOPLASM AND FAMILIAR ANAMNESIS | 1.5 Abstract in rivista | 2009 | M., Colantuoni; Carlomagno, Chiara; L., Cannella; S., Alfieri; DE STEFANO, Alfonso; Ca, Cella; DE PLACIDO, Sabino | |
Phase I-II study of xelox and bevacizumab plus erlotinib in sequential combination (XELOX-TARAV) in first line colorectal cancer: run in part | 1.5 Abstract in rivista | 2007 | G., Tortora; Carlomagno, Chiara; Bianco, Roberto; Daniele, G; Pepe, S; Leopardo, D; Marciano, Roberta; DE LAURENTIIS, Michelino; F., Ciardiello; DE PLACIDO, Sabino | |
Double complete response in MCRC patient | 1.5 Abstract in rivista | 2009 | DE STEFANO, Alfonso; Carlomagno, Chiara; L., Cannella; S., Alfieri; M., Colantuoni; Ca, Cella; DE PLACIDO, Sabino | |
Raltitrexed versus standard leucovorin-modulated 5Fluorouracil: results form the randomized phase III Pan-European Trial in Adjuvant Colon Cancer 01 (PETACC-1). | 1.1 Articolo in rivista | 2008 | Popov, I; Carrato, A; Sobrero, A; Vincent, M; Kerr, D; Labianca, R; Bianco, Ar; El Serafi, M; Bedenne, L; Paillot, B; Mini, E; Sanches, E; Welch, J; Colette, L; Praet, M; Wils, J; Carlomagno, Chiara | |
Combination chemotherapy with CMF (Cyclophosphamide, Metotrexate, 5-Fluorouracil versus CNF (Mitoxantrone, Fluorouracil, Cyclophosphamide) in advanced breast cancer. A multicenter randomized study. | 1.1 Articolo in rivista | 1993 | Lorusso, V.; De Lena, M.; Lopez, M.; DE PLACIDO, Sabino; Vici, P.; Piano, A.; Palomba, G.; Carlomagno, Chiara; D’Aprile, M.; Fosser, V.; Brandi, M.; Bianco, A. R. | |
Effect of p53 Activity on the Sensitivity of Human Glioblastoma Cells to PARP-1 Inhibitor in Combination with Topoisomerase I Inhibitor or Radiation | 1.1 Articolo in rivista | 2014 | Francesco, Sabbatino; Celeste, Fusciello; Domenico, Somma; Pacelli, Roberto; Ravin, Poudel; David, Pepin; Leonardi, Antonio; Carlomagno, Chiara; Giuseppina Della Vittoria, Scarpati; Soldano, Ferrone; Stefano, Pepe | |
Ipilimumab in the treatment of metastatic melanoma: management of adverse events | 1.1 Articolo in rivista | 2014 | Giuseppina Della Vittoria, Scarpati; Celeste, Fusciello; Francesco, Perri; Francesco, Sabbatino; Soldano, Ferrone; Carlomagno, Chiara; Stefano, Pepe | |
Predictive factors of complete response to neoadjuvant chemoradiotherapy in patients with rectal cancer | 1.1 Articolo in rivista | 2010 | Carlomagno, Chiara; Stefano, Pepe; D'Armiento, FRANCESCO PAOLO; D'Armiento, Maria; Lucia, Cannella; DE STEFANO, Alfonso; Anna, Crispo; Marcella, Giordano; DE PLACIDO, Sabino | |
Bevacizumab maintenance in metastatic colorectal cancer: How long? | 1.1 Articolo in rivista | 2014 | DE STEFANO, Alfonso; Moretto, R; Cella, Ca; Romano, Fj; Raimondo, L; Fiore, G; Di Pietro, F; Pepe, S; DE PLACIDO, Sabino; Carlomagno, Chiara | |
Cancro del colon-retto | 2.1 Contributo in volume (Capitolo o Saggio) | 2003 | Carlomagno, Chiara; DE PLACIDO, Sabino; Bianco, Ar | |
Bevacizumab related arterial hypertension as a predictive marker in metastatic Colorectal Cancer (mCRC) patients | 1.1 Articolo in rivista | 2011 | DE STEFANO, Alfonso; Carlomagno, Chiara; Stefano, Pepe; Bianco, Roberto; DE PLACIDO, Sabino | |
Trastuzumab-associated cardiac adverse effects in the Herceptin adjuvant trial. | 1.1 Articolo in rivista | 2007 | Suter, Tm; Procter, M; van Veldhuisen, Dj; Muscholl, M; Bergh, J; Carlomagno, Chiara; Perren, T; Passalacqua, R; Bighin, C; Klijn, Jgm; Ageev, Ft; Hitre, E; Groetz, J; Iwata, H; Knap, M; Gnant, M; Muehlbauer, S; Spence, A; Gelber, Rd; Piccart, M. | |
Measurement of neovascularization is an independent prognosticator of survival in node-negative breast cancer patients with long-lerm follow-up. | 1.1 Articolo in rivista | 1999 | DE PLACIDO, Sabino; Carlomagno, Chiara; Ciardiello, F; DE LAURENTIIS, Michelino; Pepe, Stefano; Ruggiero, A; Tortora, Giampaolo; Panico, L; D’ ANTONIO, A; Pettinato, Guido; Petrella, Giuseppe; Bianco, Ar | |
Bevacizumab as 4th line treatment in metastatic colorectal cancer | 1.5 Abstract in rivista | 2009 | L., Cannella; Carlomagno, Chiara; DE STEFANO, Alfonso; S., Alfieri; M., Colantuoni; Ca, Cella; DE PLACIDO, Sabino | |
EGFR mutations detected on cytology samples by a centralized laboratory reliably predict response to gefitinib in non-small cell lung carcinoma patients. | 1.1 Articolo in rivista | 2013 | Malapelle, Umberto; Bellevicine, Claudio; DE LUCA, Caterina; Salatiello, M; DE STEFANO, Alfonso; Rocco, D; de Rosa, N; Vitiello, F; Russo, S; Pepe, F; Iaccarino, A; Micheli, P; Illiano, A; Carlomagno, Chiara; Piantedosi, Fv; Troncone, Giancarlo | |
Poly(adenosine diphosphate-ribose) polymerase 1 expression in malignant melanomas from photoexposed areas of the head and neck region. | 1.1 Articolo in rivista | 2005 | Staibano, Stefania; Pepe, S; Lo Muzio, L; Somma, P; Mascolo, Massimo; Argenziano, G; Scalvenzi, Massimiliano; Salvatore, G; Fabbrocini, Gabriella; Molea, Guido; Bianco, Ar; Carlomagno, Chiara; DE ROSA, Gaetano |